^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    177Lu-LNC1010

    i
    Other names: 177Lu-LNC1010, 177Lu-TATE-EB-01, 177Lu-EB-LM3, 177Lu-Evans blue(EB)-LM3
    Associations

    News

    Trials
    Company:
    Dongcheng Pharma, Xiamen University
    Drug class:
    Ionizing radiation emitter, SSTR2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    Evaluation of 177Lu-TATE-EB-01（LNC1010）in SSTR2-positive Tumors (clinicaltrials.gov)
    P1/2, N=30, Recruiting, The First Affiliated Hospital of Xiamen University | Phase classification: P1 --> P1/2 | N=20 --> 30
    Phase classification • Enrollment change
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive • SSTR Expression
    |
    177Lu-LNC1010
    over2years
    177Lu-EB-LM3 in Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P1, N=20, Recruiting, The First Affiliated Hospital of Xiamen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive • SSTR Expression
    |
    177Lu-LNC1010
    over2years
    177Lu-EB-LM3 in Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, The First Affiliated Hospital of Xiamen University
    New P1 trial
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive • SSTR Expression
    |
    177Lu-LNC1010